MARKET

JSPR

JSPR

Jasper Therapeutics Inc
NASDAQ
0.7994
+0.0899
+12.67%
Pre Market: 0.7800 -0.0194 -2.43% 07:19 08/11 EDT
OPEN
0.7500
PREV CLOSE
0.7095
HIGH
0.8200
LOW
0.7161
VOLUME
780
TURNOVER
0
52 WEEK HIGH
3.140
52 WEEK LOW
0.3151
MARKET CAP
22.39M
P/E (TTM)
-0.2478
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at JSPR last week (0803-0807)?
Weekly Report · 1d ago
Jasper Therapeutics Halts Briquilimab Extension Study in Chronic Urticaria: What Investors Should Know
TipRanks · 4d ago
JSPR Completes Briquilimab Trial In Chronic Hives, Setting Up Next Risk–Reward Catalyst
TipRanks · 4d ago
Jasper Therapeutics Shareholders Back Board, Auditors, Pay Plan
TipRanks · 08/03 22:31
Weekly Report: what happened at JSPR last week (0727-0731)?
Weekly Report · 08/03 09:41
Jasper Therapeutics Completes Kira Pharmaceuticals Acquisition, Issues CVRs
TipRanks · 07/31 10:33
Weekly Report: what happened at JSPR last week (0720-0724)?
Weekly Report · 07/27 09:43
Weekly Report: what happened at JSPR last week (0713-0717)?
Weekly Report · 07/20 09:41
More
About JSPR
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting mast cell-driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU), and Asthma. Its lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the c-Kit receptor, inhibiting signaling for mast cells and a maintenance signal for hematopoietic stem cells. KIT inhibition with briquilimab has demonstrated clinical outcomes both as a conditioning agent for stem cell transplant in SCID and Fanconi anemia. Its pipeline also includes KP-104 (vensobafusp alfa), a bifunctional complement inhibitor in clinical development, and KP-701, a preclinical B-cell receptor-targeted therapy.

Webull offers Jasper Therapeutics Inc stock information, including NASDAQ: JSPR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JSPR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading JSPR stock methods without spending real money on the virtual paper trading platform.